Rhapsogen is a therapeutics company developing a novel mechanism to treat autoimmune diseases. Rhapsogen is co-founded by Catalio Capital Venture Partner Dr. Jeffery Ravetch.

Rhapsogen is developing a novel biologic drug class that modulates antibody effector function to blunt tissue damage and inflammation associated with autoantibody driven autoimmune conditions while preserving antibodies’ capacity to neutralize viruses and other pathogens. This mechanism could serve as a safer and more effective alternative to existing standard of care and the emergent therapeutic pipeline, including B cell and IgG depleting therapies, in a large number of autoimmune indications with high unmet need.